Relationship of high-molecular-weight adiponectin levels to visceral fat accumulation in hemodialysis patients

Internal Medicine

Volumn 49, Issue 4, 2010, Pages 299-305

  Tamei, Noriko ^a,b   Ogawa, Tetsuya ^a   Ishida, Hideki ^b   Ando, Yoshitaka ^b   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Hidaka Hospital   (Japan)

Author keywords

Adiponectin; Body mass index; HDL cholesterol; Hemodialysis; Visceral fat area

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID STORAGE; MALE; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BODY MASS INDEX; CHOLESTEROL, HDL; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MOLECULAR WEIGHT; RENAL DIALYSIS; SEX CHARACTERISTICS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77749242399     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2905     Document Type: Article

References (37)

1. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792, 2006.
2. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24: 29-33, 2004.
3. Funahashi T, Matsuzawa Y. Metabolic syndrome: Clinical concept and molecular basis. Ann Med 39: 482-494, 2007.
4. Shibata R, Izumiya Y, Sato K, et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 42: 1065-1074, 2007.
5. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function. J Clin Invest 118: 1645-1656, 2008.
6. Odamaki M, Furuya R, Ohkawa S, et al. Altered abdominal fat distribution and its association with the serum lipid profile in nondiabetic heamodialysis patients. Nephrol Dial Transplant 14: 2427-2432, 1999.
7. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94: e27-e31, 2004.
8. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 91: 3873-3877, 2006.
9. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29: 1357-1362, 2006.
10. Stenvinkel P, Marchlewska A, Pecoits-Filho R, et al. Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65: 274-281, 2004.
11. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular event among patients with endstage renal disease. J Am Soc Nephrol 13: 134-141, 2002.
12. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Upregulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 22: 171-178, 2007.
13. Sawara Y, Takei T, Uchida K, Tsuchiya K, Nitta K. Metabolic syndrome and anthropometric factors in Japanese patients with chronic kidney disease. Heart Vessles 24: 199-203, 2009.
14. Takahashi M, Otsubo S, Uchida K, Yumura W, Nitta K. Association between serum adiponectin levels and arteriosclerosis in IgA nephropathy patients. Intern Med 46: 453-459, 2007.
15. Okano K, Ohba T, Matsugami K, Uchida K, Nitta K, Kabaya T. Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. Intern Med 47: 1379-1386, 2008.
16. Iwasa Y, Otsubo S, Ishizuka T, Uchida K, Nitta K. Influence of serum high-molecular weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. Nephron Clin Pract 108: c226-c232, 2008.
17. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-93, 1999.
18. Yatagai T, Nagasaka S, Taniguchi A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52: 1274-1278, 2003.
19. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: 3815-3819, 2001.
20. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276: 41245-41254, 2001.
21. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46: 459-469, 2003.
22. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
23. Tarui S, Tokunaga K, Fujioka S, Matsuzawa Y. Visceral fat obesity: anthropological and pathophysiological aspects. Int J Obes 15 (suppl 2): 1-8, 1991.
24. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162, 2004.
25. Aso Y, Yamamoto R, Suetsugu M, et al. Comparison of the effects of pioglitazone and voglibose on circulating total and highmolecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with type 2 diabetes. Diabet Med 24: 962-968, 2007.
26. Imagawa A, Funahashi T, Nakamura T, et al. Eleveted serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 25: 1665-1666, 2002.
27. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 56: 2174-2177, 2007.
28. Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to development of coronary artery disease in nonobese men. Atherosclerosis 107: 239-246, 1994.
29. Odamaki M, Furuya R, Kinumura Y, et al. Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 102: c8-c13, 2006.
30. Yamauchi T, Kuno T, Takada H, et al. The impact of visceral fat on multiple risk factors and carotid atherosclerosis in chronic haemodialysis patients. Nephrol Dial Transplant 18: 1842-1847, 2003.
31. Araki T, Emoto M, Yokoyama H, et al. The association of plasma adiponectin level with carotid arterial stiffness. Metabolism 55: 587-592, 2006.
32. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens 18: 1543-1548, 2005.
33. Aso Y, Yamamoto R, Wakabayashi S, et al. Comparison of serum high molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using an oval enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 55: 1954-1960, 2006.
34. Inoue T, Kotooka N, Morooka T, et al. High molecular adiponectin as a predictor of longterm clinical outcome in patients with coronary artery disease. Am J Cardiol 100: 569-574, 2007.
35. Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implications as a risk of cardiovascular disease. Am J Cardiol 98: 1603-1608, 2006.
36. Diez JJ, Iglesias P, Fernandez-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol 62: 242-249, 2005.
37. Ignacy W, Chudek J, Adamczak M, et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease - a follow-up study. Nephron Clin Pract 101: c18-c24, 2005.